These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 2517351)

  • 1. Chromogenic substrates for activated partial thromboplastin time testing: are they worth using?
    Tripodi A
    Ric Clin Lab; 1989; 19(4):355-8. PubMed ID: 2517351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Automated amidolytic method for evaluating the activated partial thromboplastin time compared with a conventional coagulation method.
    Tripodi A; Poggio M; Scapellato L; Mannucci PM
    Haemostasis; 1989; 19(4):205-12. PubMed ID: 2509308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to Optimize Activated Partial Thromboplastin Time (APTT) Testing: Solutions to Establishing and Verifying Normal Reference Intervals and Assessing APTT Reagents for Sensitivity to Heparin, Lupus Anticoagulant, and Clotting Factors.
    Favaloro EJ; Kershaw G; Mohammed S; Lippi G
    Semin Thromb Hemost; 2019 Feb; 45(1):22-35. PubMed ID: 30630206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Actin FS and Actin FSL sensitivity to specific clotting factor deficiencies.
    Lawrie AS; Kitchen S; Purdy G; Mackie IJ; Preston FE; Machin SJ
    Clin Lab Haematol; 1998 Jun; 20(3):179-86. PubMed ID: 9681235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Q analyzer, a new cap-piercing fully automated coagulometer with clotting, chromogenic, and immunoturbidometric capability.
    Kitchen S; Woolley A
    Blood Coagul Fibrinolysis; 2013 Jan; 24(1):28-34. PubMed ID: 23249565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A clinical evaluation of automated chromogenic tests as substitutes for conventional prothrombin time and activated partial thromboplastin time tests.
    Duncan A; Bowie EJ; Owen CA; Fass DN
    Clin Chem; 1985 Jun; 31(6):853-5. PubMed ID: 3995763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A computer-based model to assess costs associated with the use of factor VIII and factor IX one-stage and chromogenic activity assays.
    Kitchen S; Blakemore J; Friedman KD; Hart DP; Ko RH; Perry D; Platton S; Tan-Castillo D; Young G; Luddington RJ
    J Thromb Haemost; 2016 Apr; 14(4):757-64. PubMed ID: 26748742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of Activated Partial Thromboplastin Time (APTT): Determining Reagent Sensitivity to Factor Deficiencies, Heparin, and Lupus Anticoagulants.
    Kershaw G
    Methods Mol Biol; 2017; 1646():75-83. PubMed ID: 28804819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Qualification of a select one-stage activated partial thromboplastin time-based clotting assay and two chromogenic assays for the post-administration monitoring of nonacog beta pegol.
    Tiefenbacher S; Bohra R; Amiral J; Bowyer A; Kitchen S; Lochu A; Rosén S; Ezban M
    J Thromb Haemost; 2017 Oct; 15(10):1901-1912. PubMed ID: 28772338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of a centrifugal analyzer for a chromogenic prothrombin time, a chromogenic activated partial thromboplastin time and a kinetic fibrinogen assay in a routine hospital laboratory.
    de Metz M; van Wersch JW
    Haemostasis; 1987; 17(5):254-9. PubMed ID: 3666583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of the activated partial thromboplastin time for the diagnosis of congenital coagulation disorders: problems and possible solutions.
    Barna L; Triplett DA
    Ric Clin Lab; 1989; 19(4):345-54. PubMed ID: 2517350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recommendations for appropriate activated partial thromboplastin time reagent selection and utilization.
    Fritsma GA; Dembitzer FR; Randhawa A; Marques MB; Van Cott EM; Adcock-Funk D; Peerschke EI
    Am J Clin Pathol; 2012 Jun; 137(6):904-8. PubMed ID: 22586049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of chromogenic vs clot.based one stage APTT assay for determination of factor VIII level.
    Baig MA; Swamy KB
    Indian J Pathol Microbiol; 2021; 64(1):123-127. PubMed ID: 33433421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coagulation Testing in the Core Laboratory.
    Winter WE; Flax SD; Harris NS
    Lab Med; 2017 Nov; 48(4):295-313. PubMed ID: 29126301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-step chromogenic equivalent of activated partial thromboplastin time evaluated for clinical application.
    Ponjee GA; Vader HL; de Wild PJ; Janssen GW; van der Graaf F
    Clin Chem; 1991 Jul; 37(7):1235-44. PubMed ID: 1855296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A rapid screen for lupus anticoagulant with good discrimination from oral anticoagulants, congenital factor deficiency and heparin, is provided by comparing a sensitive and an insensitive APTT reagent.
    Brancaccio V; Ames PR; Glynn J; Iannaccone L; Mackie IJ
    Blood Coagul Fibrinolysis; 1997 Apr; 8(3):155-60. PubMed ID: 9167015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Easy Method to Eliminate the Effect of Lupus Anticoagulants in the Coagulation Factor Assay.
    Tang N; Yin S
    Clin Lab; 2016 Jul; 62(7):1363-1365. PubMed ID: 28164630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Verification of the guidelines for lupus anticoagulant detection: usefulness of index for circulating anticoagulant in APTT mixing test.
    Kumano O; Ieko M; Naito S; Yoshida M; Takahashi N; Suzuki T; Aoki T
    Thromb Res; 2014 Aug; 134(2):503-9. PubMed ID: 24935674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Contact factor deficiencies and cardiopulmonary bypass surgery: detection of the defect and monitoring of heparin.
    van Veen JJ; Laidlaw S; Swanevelder J; Harvey N; Watson C; Kitchen S; Makris M
    Eur J Haematol; 2009 Mar; 82(3):208-12. PubMed ID: 19077049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro sensitivity of different activated partial thromboplastin time reagents to mild clotting factor deficiencies.
    Toulon P; Eloit Y; Smahi M; Sigaud C; Jambou D; Fischer F; Appert-Flory A
    Int J Lab Hematol; 2016 Aug; 38(4):389-96. PubMed ID: 27185477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.